Lab21 secures European and USA patents for HCV drug resistance genotyping

18-May-2012 - United Kingdom

Lab21 Limited has secured new patents in Europe and the USA relating to hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.  

The patents cover technology allowing the genotypic identification of drug resistant mutations in the four major global genotypes of HCV. The new patents represent successful extensions of the original European approval, granted in 2009. The US patent is the first successful patent Lab21 has secured in North America to protect its growing business.

Dr Berwyn Clarke, CSO at Lab21 commented: ‘Lab21 has extensive experience in the area of antiretroviral drug resistance from many years of working in HIV.  With the number of new HCV therapeutics in development and the changeable nature of the virus, we expect routine resistance analysis for HCV patients to be introduced into clinical guidelines in the near future.  Our IP in this area will be of great importance to the clinical management of these patients and will enable easy drug resistance monitoring during clinical trials.

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae

RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.

RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics

Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030

Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology

Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology

U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases

NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD

Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026

Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026

Midatech and Immunotope Form Joint Venture, Syntara LLC, for the Development of Immune Therapies

Singapore Launches Infrastructure for Metrology in Chemistry (MiC)

Portable and precise gas sensor could monitor pollution and detect disease

BIOTECON Diagnostics GmbH and Xiril AG start worldwide sales cooperation